Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans

Neuropharmacology

Volumn 67, Issue , 2013, Pages 476-484

  Orrú, Marco ^a   Guitart, Xavier ^a   Karcz Kubicha, Marzena ^a   Solinas, Marcello ^a,b   Justinova, Zuzana ^a   Barodia, Sandeep Kumar ^a   Zanoveli, Janaina ^a,d   Cortes, Antoni ^c   Lluis, Carme ^c   Casado, Vicent ^c   Moeller, F Gerard ^e   Ferré, Sergi ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b INSERM   (France)

^c UNIVERSITY OF BARCELONA   (Spain)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Caffeine; Dopamine release; Drug discrimination; Paraxanthine; Phosphodiesterase inhibitor; Psychostimulant; Rat striatum

Indexed keywords

CAFFEINE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; EX VIVO STUDY; EXTRACELLULAR SPACE; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSTIMULANT ACTIVITY; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; THEOPHYLLINE;

EID: 84873331768     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.11.029     Document Type: Article

References (59)

1. K. Antoniou, Z. Papadopoulou-Daifoti, T. Hyphantis, G. Papathanasiou, E. Bekris, and M. Marselos A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors Psychopharmacology 183 2005 154 162
2. 14C] caffeine in rats, mice, and Chinese hamsters Drug Metab. Dispos. 13 1985 471 478
3. M.J. Arnaud Pharmacokinetics and metabolism of natural methylxanthines in animal and man Handb. Exp. Pharmacol. 200 2011 33 91
4. J. Baumgold, O. Nikodijevic, and K.A. Jacobson Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding Biochem. Pharmacol. 43 1992 889 894
5. A.T. Bender, and J.A. Beavo Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol. Rev. 58 2006 488 520
6. N.L. Benowitz, P. Jacob 3rd, H. Mayan, and C. Denaro Sympathomimetic effects of paraxanthine and caffeine in humans Clin. Pharmacol. Ther. 58 1995 684 691
7. F. Berthou, D. Ratanasavanh, D. Alix, D. Carlhant, C. Riche, and A. Guillouzo Caffeine and theophylline metabolism in newborn and adult human hepatocytes: comparison with adult rat hepatocytes Biochem. Pharmacol. 37 1988 3691 3700
8. F. Berthou, B. Guillois, C. Riche, Y. Dreano, E. Jacqz-Aigrain, and P.H. Beaune Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes Xenobiotica 22 1992 71 80
9. J. Borycz, M.F. Pereira, A. Melani, R.J. Rodrigues, A. Köfalvi, and L. Panlilio Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments J. Neurochem. 101 2007 355 363
10. R.W. Butcher, and E.W. Sutherland Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine J. Biol. Chem. 237 1962 1244 1250
11. J.M. Carney, T.W. Seale, L. Logan, and S.B. McMaster Sensitivity of inbred mice to methylxanthines is not determined by plasma xanthine concentration Neurosci. Lett. 56 1985 27 31
12. 1 adenosine receptor from pig brain: characterization and evidence of the role of the cell membrane on the coexistence of high-and low-affinity states J. Neurosci. Res. 26 1990 461 473
13. L.E. Collins, D.J. Galtieri, P. Collins, S.K. Jones, R.G. Port, and N.E. Paul Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity Behav. Brain Res. 211 2010 148 155
14. G. Di Chiara, V. Bassareo, S. Fenu, M.A. De Luca, L. Spina, and C. Cadoni Dopamine and drug addiction: the nucleus accumbens shell connection Neuropharmacology 47 Suppl. 1 2004 227 241
15. K.U. Domek-Łopacińska, and J.B. Strosznajder Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease Mol. Neurobiol. 41 2010 129 137
16. M. El Yacoubi, C. Ledent, J.F. Ménard, M. Parmentier, J. Costentin, and J.M. Vaugeois The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors Br. J. Pharmacol. 129 2000 1465 1473
17. D.M. Essayan Cyclic nucleotide phosphodiesterases J. Allergy Clin. Immunol. 108 2001 671 680
18. S. Ferré, T. Guix, J. Sallés, A. Badia, P. Parra, and F. Jané Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes Eur. J. Pharmacol. 179 1990 295 299
19. S. Ferré, M. Herrera-Marschitz, M. Grabowska-Andén, U. Ungerstedt, M. Casas, and N.-E. Andén Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice Eur. J. Pharmacol. 192 1991 36 42
20. S. Ferré An update on the mechanisms of the psychostimulant effects of caffeine J. Neurochem. 105 2008 1067 1079
21. G. Fisone, A. Borgkvist, and A. Usiello Caffeine as a psychomotor stimulant: mechanism of action Cell. Mol. Life Sci. 61 2004 857 872
22. S.H. Francis, M.A. Blount, and J.D. Corbin Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions Physiol. Rev. 91 2011 651 690
23. B.B. Fredholm, and K. Lindström Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A(2A) receptors Eur. J. Pharmacol. 380 1999 197 202
24. B.B. Fredholm, and C.G. Persson Xanthine derivatives as adenosine receptor antagonists Eur. J. Pharmacol. 81 1982 673 676
25. J. Garthwaite Concepts of neural nitric oxide-mediated transmission Eur. J. Neurosci. 27 2008 2783 2802
26. M. Gasior, M. Jaszyna, P. Munzar, J.M. Witkin, and S.R. Goldberg Caffeine potentiates the discriminative-stimulus effects of nicotine in rats Psychopharmacology 162 2002 385 395
27. S.R. Goldberg, J.A. Prada, and J.L. Katz Stereoselective behavioral effects of N6-phenylisopropyl-adenosine and antagonism by caffeine Psychopharmacology 87 1985 272 277
28. 2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease J. Org. Chem. 69 2004 3308 3318
29. Y. Itzhak Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase J. Pharmacol. Exp. Ther. 282 1997 521 527
30. 2A receptors in the motor effects of caffeine after its acute and chronic administration Neuropsychopharmacology 28 2003 1281 1291
31. H. Kayir, and I.T. Uzbay Evidence for the role of nitric oxide in caffeine-induced locomotor activity in mice Psychopharmacology 172 2004 11 15
32. A. Lelo, G. Kjellen, D.J. Birkett, and J.O. Miners Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine J. Pharmacol. Exp. Ther. 248 1989 315 319
33. S.M. Li, L.L. Yin, J. Shi, Z.B. Lin, and J.W. Zheng The effect of 7-nitroindazole on the acquisition and expression of d-methamphetamine-induced place preference in rats Eur. J. Pharmacol. 435 2002 217 223
34. M. Lindskog, P. Svenningsson, L. Pozzi, Y. Kim, A.A. Fienberg, and J.A. Bibb Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine Nature 418 2002 774 778
35. A. Nehlig, J.L. Daval, and G. Debry Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects Brain Res. Rev. 17 1992 139 170
36. M. Okuro, N. Fujiki, N. Kotorii, Y. Ishimaru, P. Sokoloff, and S. Nishino Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice Sleep 33 2010 930 942
37. M. Orrú, J. Bakešová, M. Brugarolas, C. Quiroz, V. Beaumont, and S.R. Goldberg Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists PLoS One 6 2011 e16088
38. 2A receptors in the rat striatum Neuropharmacology 61 2011 967 974
39. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates sixth ed. 2006
40. E. Przegaliński, and M. Filip Nitric oxide (NO) pathway and locomotor hyperactivity towards dopaminomimetics in rats Pol. J. Pharmacol. 49 1997 291 298
41. D. Quarta, S. Ferré, M. Solinas, Z.B. You, J. Hockemeyer, and P. Popoli Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure J. Neurochem. 88 2004 1151 1158
42. P.A. Randall, E.J. Nunes, S.L. Janniere, C.M. Stopper, A.M. Farrar, and T.N. Sager Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists Psychopharmacology 216 2011 173 186
43. E. Reyes-Irisarri, M. Markerink-Van Ittersum, G. Mengod, and J. de Vente Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains Eur. J. Neurosci. 25 2007 3332 3338
44. S. Sarrió, V. Casadó, M. Escriche, F. Ciruela, J. Mallol, E.I. Canela, C. Lluis, and R. Franco The heat shock cognate protein hsc73 assembles with A(1) adenosine receptors to form functional modules in the cell membrane Mol. Cell. Biol. 20 2000 5164 5174
45. T.W. Seale, P. Johnson, J.M. Carney, and O.M. Rennert Interstrain variation in acute toxic response to caffeine among inbred mice Pharmacol. Biochem. Behav. 20 1984 567 573
46. D. Shi, and J.W. Daly Chronic effects of xanthines on levels of central receptors in mice Cell. Mol. Neurobiol. 19 1999 719 732
47. S.H. Snyder, J.J. Katims, Z. Annau, R.F. Bruns, and J.W. Daly Adenosine receptors and behavioral actions of methylxanthines Proc. Natl. Acad. Sci. U. S. A. 78 1981 3260 3264
48. S.H. Snyder Nitric oxide: first in a new class of neurotransmitters Science 257 1992 494 496
49. M. Solinas, S. Ferré, Z.B. You, M. Karcz-Kubicha, P. Popoli, and S.R. Goldberg Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens J. Neurosci. 22 2002 6321 6324
50. M. Solinas, S. Ferré, K. Antoniou, D. Quarta, Z. Justinova, and J. Hockemeyer Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats Psychopharmacology 179 2005 576 586
51. B. Stavric Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines Food Chem. Toxicol. 26 1988 725 733
52. J. Stewart, S.E. Deschamps, and S. Amir Inhibition of nitric oxide synthase does not block the development of sensitization to the behavioral activating effects of amphetamine Brain Res. 641 1994 141 144
53. E.W. Sutherland, and T.W. Rall Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles J. Biol. Chem. 232 1958 1077 1091
54. P. Svenningsson, G.G. Nomikos, and B.B. Fredholm Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration J. Neurosci. 15 1995 7612 7624
55. F.J. Van der Staay, K. Rutten, L. Bärfacker, J. Devry, C. Erb, and H. Heckroth The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents Neuropharmacology 55 2008 908 918
56. W.C. Van Staveren, and M. Markerink-van Ittersum Localization of cyclic guanosine 3′,5′-monophosphate-hydrolyzing phosphodiesterase type 9 in rat brain by nonradioactive in situ hydridization Methods Mol. Biol. 307 2005 75 84
57. S.R. Vincent, and H. Kimura Histochemical mapping of nitric oxide synthase in the rat brain Neuroscience 46 1992 755 784
58. M.R. Zarrindast, M. Karami, H. Sepehri, and H. Sahraei Influence of nitric oxide on morphine-induced conditioned place preference in the rat central amygdala Eur. J. Pharmacol. 453 2002 81 89
59. M.R. Zarrindast, A. Gholami, H. Sahraei, and A. Haeri-Rohani Role of nitric oxide in the acquisition and expression of apomorphine- or morphine-induced locomotor sensitization J. Pharmacol. 482 2003 205 213